Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder.
Corá-Locatelli
G
G
Greenberg
B D
BD
Martin
J
J
Murphy
D L
DL
D000085:Acetates / Q000627:therapeutic use*; D000588:Amines; D000927:Anticonvulsants / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005473:Fluoxetine / Q000627:therapeutic use*; D000077206:Gabapentin; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D010865:Pilot Projects; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005473:Fluoxetine; D000077206:Gabapentin; D017367:Selective Serotonin Reuptake Inhibitors; D005680:gamma-Aminobutyric Acid